PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.73%
EBIT growth of 10.73% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
2.45%
Positive operating income growth while Biotechnology is negative. Peter Lynch would spot a big relative advantage here.
10.71%
Net income growth of 10.71% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
23.59%
EPS growth of 23.59% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
23.59%
Diluted EPS growth of 23.59% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
16.70%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
16.70%
Diluted share change of 16.70% while Biotechnology median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-19.06%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-18.45%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-42182.97%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-53680.51%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-38238.10%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-21634.42%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-19064.37%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-68658.62%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-3403.93%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-569.70%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-664.70%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-169.45%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
6.82%
R&D growth of 6.82% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-13.19%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.